Shots:

• Forendo to receive up front- equity investment- development- regulatory and commercial milestones with royalties on sales. Novartis to fund the research activities and will be responsible for development- manufacturing & commercialization of novel therapies
• Forendo has its expertise in an enzyme family called HSD17B (17-beta-hydroxysteroid dehydrogenase) responsible for regulating hormone action with its lead candidate- FOR-6219 currently being evaluated in P-I clinical study for endometriosis
• With the collaboration- Novartis acknowledges Forendo's core capabilities and the scope of its enzyme family in other therapeutic areas in addition to women's health

Source 1- Source 2 to­ read full press release/ article | Ref: GlobeNewswire- PRNewswire | Image: Forendo Pharma